Actively Recruiting
Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
Led by Taipei Veterans General Hospital, Taiwan · Updated on 2026-04-30
120
Participants Needed
1
Research Sites
333 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease. The study will also evaluate the safety of these treatments. The main questions it aims to answer are: * Does statin therapy change disease activity, as measured by changes in the Clinical Activity Score (CAS) and proptosis? * Does vitamin D supplementation change disease activity in patients with active thyroid eye disease? * Does combined treatment with statin and vitamin D produce different effects compared with either treatment alone or standard care? * What adverse events occur during treatment? Researchers will compare four groups: standard care alone, statin therapy plus standard care, vitamin D supplementation plus standard care, and combined statin and vitamin D therapy plus standard care. Participants will: * Be randomly assigned to one of four treatment groups * Receive the assigned treatment for 24 weeks * Attend clinic visits for clinical assessments and blood tests at baseline and at 24 weeks * Be followed through medical record review for up to three years after completion of the intervention
CONDITIONS
Official Title
Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 20 years or older
- Diagnosis of active thyroid eye disease with a Clinical Activity Score (CAS) of 3 or higher
- Low-density lipoprotein cholesterol (LDL-C) level of 100 mg/dL or higher
You will not qualify if you...
- Prior orbital radiotherapy or orbital surgery for thyroid eye disease
- Use of statins or high-dose vitamin D supplementation (greater than 400 IU per day) within 3 months prior to enrollment
- Pregnancy
- Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m�b2
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan, 11217
Actively Recruiting
Research Team
C
Chin-Sung Kuo, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here